Fluid delivery system with optical sensing of analyte concentration levels

• US 20100298764A1
• Filed: 09/05/2007
• Published: 11/25/2010
• Est. Priority Date: 09/06/2006
• Status: Abandoned Application

• Current Assignee: Roche Diabetes Care Inc. (Roche Holding AG)
• Original Assignee: Roche Diabetes Care Inc. (Roche Holding AG)
• Inventors: Iddan, Gavriel J., Shapira, Gali, Yodfat, Ofer, Kaidar, Ruthy
• Application Number:
  US11/989,678
• Publication Number:
  US 20100298764A1
• Time in Patent Office: Days
• US Class Current: 604/66
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61M 2005/14268 with a reusable and a disposable component
• CPC Class Codes: A61M 5/14248 of the skin patch type
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00

Abstract

A system for continuous monitoring of body analytes and controlling delivery of fluids to a body of a user. The system includes a sensing apparatus configured to detect concentration level of analyte in the body of the user using optical means and a dispensing apparatus configured to infuse fluid into the body of the user based on the detected concentration level of analyte.

Claims

1. A system for continuous monitoring of one or more body analytes and controlling delivery of fluids to a body of a patient, comprising:

a sensing apparatus configured to detect concentration level of an analyte in the body of the patient using optical means; and

a dispensing apparatus configured to infuse fluid into the body of the patient based on the detected concentration level of the analyte, wherein

the sensing apparatus and the dispensing apparatus use a subcutaneous cannula.

2. The system according to claim 1, further comprising a controller configured to regulate dispensing of a fluid based on a detected concentration level of analyte in the body of the patient.

3. The system according to claim 2, wherein the controller is further configured to regulate dispensing of a fluid based on a detected concentration level of analyte in the body of the patient and external inputs.

4. The system according to claim 1, wherein the optical means comprises spectroscopic analysis means.

5. The system according to claim 1, wherein the analyte is glucose.

6. The system according to claim 1, wherein the infused fluid is insulin.

7. The system according to claim 1, wherein the sensing apparatus is a non-invasive sensing apparatus configured to non-invasively detect concentration level of analyte.

8. The system according to claim 1, wherein the sensing apparatus is a minimally-invasive sensing apparatus configured to detect concentration level of analyte, and the sensing apparatus includes a cannula configured for insertion into a subcutaneous tissue of the skin of the patient and to monitor level of interstitial fluid (“

ISF”

) analyte.

9. The system according to claim 8, wherein the sensing apparatus is a skin adhesive device is configured to utilize micropores made in the skin of the patient to monitor level of ISF analyte.

10. The system according to claim 8, wherein the cannula comprises a semi-permeable membrane configured to enable diffusion and selectively allow entry of analyte molecules into the cannula, wherein a concentration of analyte in the fluid within the cannula is substantially proportional to a concentration of analyte in the interstitial fluid outside the cannula.

11. The system according to claim 1, wherein the optical means is configured to spectroscopically analyze the analyte using technology selected from the group consisting of:

near infra red (NIR) reflectance, mid-infra red (IR) spectroscopy, light scattering, Raman scattering, polarimetry, and photoacoustic spectroscopy.

12. The system according to claim 11, wherein the optical means further comprises:

at least one light-emitting unit having a source of light;

a measurement cell unit for receiving an analyte-rich fluid, said measurement cell unit is configured to allow passage of light for measurement of level of concentration of analyte;

at least one detector unit configured to detect the light after it passed through the measurement cell unit prior to analysis of level of concentration of analyte; and

at least one reflector unit configured to direct light emitted by the light-emitting unit through the analyte-rich fluid located in the measurement cell unit.

13. The system according to claim 12, wherein the measurement cell unit is configured to be placed in that portion of the cannula, which is inside the body of the patient.

14. The system according to claim 12, wherein the measurement cell unit is configured to be placed in that portion of the cannula, which is outside the body of the patient.

15. A method for continuous monitoring of one or more body analytes and controlling delivery of fluids to a body of a patient, comprising:

detecting concentration level of an analyte in the body of the patient; and

infusing fluid into the body of the patient based on the detected concentration level of the analyte;

performing said detecting and said infusing a subcutaneous cannula.

16. The method according to claim 15, further comprising

regulating dispensing of a fluid based on a detected concentration level of analyte in the body of the patient.

17. The method according to claim 15, wherein the analyte is glucose.

18. The method according to claim 15, wherein the infused fluid is insulin.

19. The method according to claim 15, wherein said detecting further comprises

non-invasively detecting concentration level of analyte.

20. The method according to claim 15, wherein said detecting further comprises

minimally-invasively detecting concentration level of analyte.

21. The method according to claim 20, further comprising

inserting a cannula into a subcutaneous tissue of the skin of the patient;

and

monitoring level of an interstitial fluid (“

ISF”

) analyte.

22. The method according to claim 21, wherein said detecting further comprises

utilizing micropores made in the skin of the patient to perform said monitoring of level of ISF analyte.

23. The method according to claim 22, wherein the cannula includes a semi-permeable membrane configured to enable diffusion and selectively allow entry of analyte molecules into the cannula, wherein a concentration of analyte in the fluid within the cannula is substantially proportional to a concentration of analyte in the interstitial fluid outside the cannula.

24. The method according to claim 15, wherein said detecting further comprises

spectroscopically analyzing the analyte using technology selected from the group consisting of:

near infra red (NIR) reflectance, mid-infra red (IR) spectroscopy, light scattering, Raman scattering, polarimetry, and photoacoustic spectroscopy.

25. The method according to claim 24, wherein said spectroscopically analyzing further comprises

emitting light using a light-emitting unit having a source of light;

using a measurement cell unit for receiving an analyte-rich fluid, allowing passage of light for measurement of level of concentration of analyte;

using a detector unit, detecting the light after the light passed through the measurement cell unit prior to analysis of level of concentration of analyte; and

using a reflector unit, directing light emitted by the light-emitting unit through the analyte-rich fluid located in the measurement cell unit.

26. The method according to claim 25, wherein the measurement cell unit is configured to be placed in that portion of the cannula, which is inside the body of the patient.

27. The method according to claim 25, wherein the measurement cell unit is configured to be placed in that portion of the cannula, which is outside the body of the patient.